EDSA vs. HUGE, PIRS, AVTX, RDHL, MNPR, KPRX, COCP, PPBT, TNXP, and VAXX
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), Avalo Therapeutics (AVTX), RedHill Biopharma (RDHL), Monopar Therapeutics (MNPR), Kiora Pharmaceuticals (KPRX), Cocrystal Pharma (COCP), Purple Biotech (PPBT), Tonix Pharmaceuticals (TNXP), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical preparations" industry.
FSD Pharma (NASDAQ:HUGE) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Edesa Biotech received 25 more outperform votes than FSD Pharma when rated by MarketBeat users. Likewise, 75.76% of users gave Edesa Biotech an outperform vote while only 0.00% of users gave FSD Pharma an outperform vote.
In the previous week, FSD Pharma had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for FSD Pharma and 1 mentions for Edesa Biotech. FSD Pharma's average media sentiment score of 1.00 beat Edesa Biotech's score of 0.96 indicating that Edesa Biotech is being referred to more favorably in the news media.
Edesa Biotech has a consensus target price of $39.00, indicating a potential upside of 757.14%. Given FSD Pharma's higher possible upside, analysts clearly believe Edesa Biotech is more favorable than FSD Pharma.
1.2% of FSD Pharma shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 8.5% of FSD Pharma shares are owned by company insiders. Comparatively, 25.0% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Edesa Biotech's return on equity of -70.35% beat FSD Pharma's return on equity.
FSD Pharma has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Summary
Edesa Biotech beats FSD Pharma on 8 of the 12 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
